B cell

(redirected from B-cell)
Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to B-cell: B-cell lymphoma

B cell

[′bē ‚sel]
(immunology)
One of a heterogeneous population of bone-marrow-derived lymphocytes which participates in the immune responses. Also known as B lymphocyte.
References in periodicals archive ?
Furthermore, HMPL-523 exhibited a linear pharmacokinetic profile and a dose dependent suppression of B-cell activation.
The MUM-1 positivity and the CD10 and BCL6 negativity indicate that this lymphoma was of postgerminal center origin (activated B-cell type).
The drug also has shown potential in treating follicular non-Hodgkin's lymphoma, diffuse large B-cell lymphoma, and rheumatoid arthritis.
This immune surveillance accounts for what researchers at the institute call the 'surprising rarity' of B-cell lymphomas in the population, given how often these spontaneous changes occur.
With approval by the Italian Medicines Agency (AIFA), the company's medicinal product PIXUVRI (pixantrone) will use used as a monotherapy for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (patients with aggressive B-cell NHL who failed two or three prior lines of therapy).
Small B-cell neoplasms comprise approximately 60% of Bcell leukemias/lymphomas with an annual incidence of 16 per 100 000 in the United States, (16) whereas H/DSs are extremely infrequent, constituting much less than 1% of hematolymphoid malignancies in the Western world.
Primary cutaneous large B-cell lymphomas (leg type) (PCBLS) are diffuse large cell B-cell lymphomas with predominance or confluent sheets of centroblasts and immunoblasts.
The authors do not discuss in great detail the possible mechanisms of this relationship but they do note that several reports have focused on an oligoclonal B-cell response targeting cell surface components such as actin, which may give apoptotic signals in medullary breast cancer.
Marginal-zone B-cell lymphoma of the bony palate is uncommon.
has initiated a phase II clinical trial of SGN-40 for the treatment of patients with diffuse large B-cell lymphoma, the most common type of aggressive non-Hodgkin's lymphoma (NHL).
The patient was a 28-year-old Caucasian woman with an angioimmunoblastic T--non-Hodgkin lymphoma (NHL) that changed into a highly malignant blastic B-cell lymphoma (T-cell-rich B-NHL state I with 70% CD20+ cells, initial stage IIIB).
In 1997, Rituxan was the first monoclonal antibody approved for cancer, when it was approved for treating relapsed or refractory low-grade or follicular CD20-positive, B-cell NHL.